CD28 and splenic marginal zone lymphoma: Recently, the use of second-generation CAR-Ts targeting CD19 with stimulatory domains of CD28/4-1BB has reported considerable outcomes in the treatment of B-cell lymphomas, particularly PMBCL, DLBCL, splenic marginal zone lymphoma (SMZL), FL, and MCL (142).